The HPV vaccine has halved the prevalence of HPV in teenage girls in the US, a study performed by the Centers for Disease Control and Prevention (CDC) has shown. Among females aged 14-19 years, the vaccine-type HPV (HPV-6, -11, -16 and -18) prevalence has fallen from 11.5% in the prevaccine era (2003-2006) to 5.1% in the vaccine era – a fall of 56% (2007-2010).
The HPV vaccine was introduced into the immunization schedule in the US in 2006, but in 2010 the 3-dose vaccine coverage was just 32% among 13-17 year olds.
"These are striking results and they should be a wake-up call that we need to increase vaccinations," said Thomas Frieden, director of the Centers for Disease Control and Prevention, adding that if the vaccination rate were 80%, 50,000 cases of cervical cancer among girls alive today could be prevented. "It is possible to protect a generation from cancer and we have to do it."
Merck's Gardasil generate more than $1.6 billion in 2012 sales, while GSK's Cervarix had about $428 million in 2012 sales (Bloomberg).
The news comes as Japan's health ministry announces it is withdrawing its recommendation for the vaccine over safety concerns.
If you want to know more about strategy and innovation in vaccines, you might be interested in attending the World Vaccine Congress Europe 2013, 16-17 October 2013, Lille.